Company: PRGO
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001585364-25-000122
Chunk: 183

Company: PERRIGO Co plc
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 7
Chunk 183
---
 460.1 — 1,395.1 Gross profit343.3 409.2 — 752.4 Gross margin 26.9 %47.1 %— %35.0 %Operating expensesDistribution26.7 22.8 — 49.5 Research and development31.3 27.0 — 58.4 Selling110.3 190.1 — 300.4 Administration71.4 79.2 105.9 256.4 Impairment charges— 34.1 — 34.1 Restructuring18.6 39.8 23.0 81.3 Other operating (income) expense, net— — 54.0 54.0 Total operating expenses258.3 393.0 182.9 834.1 Operating income (loss)$85.0 $16.2 $(182.9)$(81.7)Operating income (loss) %6.6 %1.9 %NM(3.8)%Interest expense, net87.1 Other (income) expense, net3.8 Income (loss) from continuing operations before income taxes$(172.6)CSCACSCIUnallocatedTotalSix Months Ended June 29, 2024Capital expenditures$39.8 $13.7 $— $53.5 Depreciation/amortization$68.1 $95.3 $— $163.3 (1) Amounts may not add or recalculate due to rounding. Percentages are based on actuals.

NOTE 18 - SUBSEQUENT EVENTS

DivestituresOn July 13, 2025, we entered into a binding agreement to sell our Dermacosmetics branded business in Northern Europe, the Netherlands and Poland (the "Dermacosmetics Business") to Kairos Bidco AB ("Kairos") for total consideration of up to €327 million, consisting of an upfront cash payment of €300 million to be paid by Kairos at closing, subject to customary adjustments, and up to €27 million in potential earn-out payments based on the Dermacosmetics Business achieving certain performance thresholds. The transaction is expected to close during the first quarter of 2026.The criteria for reporting our Dermacosmetics Business disposal group as held for sale were met after